Giorgio Gandaglia1, Peter Albers2, Per-Anders Abrahamsson3, Alberto Briganti4, James W F Catto5, Christopher R Chapple6, Francesco Montorsi4, Nicolas Mottet7, Monique J Roobol8, Jens Sønksen9, Manfred Wirth10, Hendrik van Poppel11. 1. Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: gandaglia.giorgio@hsr.it. 2. Department of Urology, Heinrich-Heine University, Medical Faculty, Düsseldorf, Germany. 3. Department of Urology, Lund University, Malmø, Sweden. 4. Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. 5. Academic Urology Unit, University of Sheffield, Sheffield, UK. 6. Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Sheffield, UK. 7. Department of Urology, University Hospital, St. Etienne, France. 8. Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands. 9. Department of Urology, Herlev and Gentofte University Hospital, Herlev, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 10. Department of Urology, Medical Faculty Carl Gustav Carus, Technical University of Dresden, Dresden, Germany. 11. Department of Urology, University Hospital K.U. Leuven, Leuven, Belgium.
Abstract
Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe. Screening in asymptomatic men (aged 55-69yr) using prostate-specific antigen (PSA) is associated with a migration toward lower staged disease and a reduction in cancer-specific mortality. By 20yr after testing, around 100 men need to be screened to prevent one PCa death. While this ratio is smaller than for breast and colon cancer, the long natural history of PCa means many men die from other causes. As such, the nonselective use of PSA testing and radical treatments can lead to overdiagnosis and overtreatment. The European Association of Urology (EAU) supports measures to encourage appropriate PCa detection through PSA testing, while reducing overdiagnosis and overtreatment. These goals may be achieved using personalized risk-stratified approaches. For diagnosis, the greatest benefit from early detection is likely to come in men assessed using baseline PSA levels at the age of 45yr to individualize screening intervals. Multiparametric magnetic resonance imaging as well as risk calculators based on family history, ethnicity, digital rectal examination, and prostate volume should be considered to triage the need for biopsy, thus reducing the risk of overdiagnosis. For treatment, the EAU advocates balancing patient's life expectancy and cancer's mortality risk when deciding an approach. Active surveillance is encouraged in well-informed patients with low-risk and some intermediate-risk cancers, as it decreases the risks of overtreatment without compromising oncological outcomes. Conversely, the EAU advocates radical treatment in suitable men with more aggressive PCa. Multimodal treatment should be considered in locally advanced or high-grade cancers. PATIENT SUMMARY: Implementation of prostate-specific antigen (PSA)-based screening should be considered at a population level. Men at risk of prostate cancer should have a baseline PSA blood test (eg, at 45yr). The level of this test, combined with family history, ethnicity, and other factors, can be used to determine subsequent follow-up. Magnetic resonance imaging scans and novel biomarkers should be used to determine which men need biopsy and how any cancers should be treated.
Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe. Screening in asymptomatic men (aged 55-69yr) using prostate-specific antigen (PSA) is associated with a migration toward lower staged disease and a reduction in cancer-specific mortality. By 20yr after testing, around 100 men need to be screened to prevent one PCa death. While this ratio is smaller than for breast and colon cancer, the long natural history of PCa means many men die from other causes. As such, the nonselective use of PSA testing and radical treatments can lead to overdiagnosis and overtreatment. The European Association of Urology (EAU) supports measures to encourage appropriate PCa detection through PSA testing, while reducing overdiagnosis and overtreatment. These goals may be achieved using personalized risk-stratified approaches. For diagnosis, the greatest benefit from early detection is likely to come in men assessed using baseline PSA levels at the age of 45yr to individualize screening intervals. Multiparametric magnetic resonance imaging as well as risk calculators based on family history, ethnicity, digital rectal examination, and prostate volume should be considered to triage the need for biopsy, thus reducing the risk of overdiagnosis. For treatment, the EAU advocates balancing patient's life expectancy and cancer's mortality risk when deciding an approach. Active surveillance is encouraged in well-informed patients with low-risk and some intermediate-risk cancers, as it decreases the risks of overtreatment without compromising oncological outcomes. Conversely, the EAU advocates radical treatment in suitable men with more aggressive PCa. Multimodal treatment should be considered in locally advanced or high-grade cancers. PATIENT SUMMARY: Implementation of prostate-specific antigen (PSA)-based screening should be considered at a population level. Men at risk of prostate cancer should have a baseline PSA blood test (eg, at 45yr). The level of this test, combined with family history, ethnicity, and other factors, can be used to determine subsequent follow-up. Magnetic resonance imaging scans and novel biomarkers should be used to determine which men need biopsy and how any cancers should be treated.
Authors: Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan Journal: Nat Rev Urol Date: 2019-07-17 Impact factor: 14.432
Authors: Travis J Meyers; Adam B Weiner; Rebecca E Graff; Anuj S Desai; Lauren Folgosa Cooley; William J Catalona; Stephen B Hanauer; Jennifer D Wu; Edward M Schaeffer; Sarki A Abdulkadir; Shilajit D Kundu; John S Witte Journal: Int J Cancer Date: 2020-05-29 Impact factor: 7.396
Authors: David Eldred-Evans; Henry Tam; Heminder Sokhi; Anwar R Padhani; Mathias Winkler; Hashim U Ahmed Journal: Nat Rev Urol Date: 2020-07-21 Impact factor: 14.432
Authors: Bas Israël; Jos Immerzeel; Marloes van der Leest; Gerjon Hannink; Patrik Zámecnik; Joyce Bomers; Ivo G Schoots; Jean-Paul van Basten; Frans Debruyne; Inge van Oort; Michiel Sedelaar; Jelle Barentsz Journal: BJU Int Date: 2021-08-23 Impact factor: 5.969